Groundbreaking trial tests twice-yearly injection for stubborn high blood pressure

A large-scale clinical trial has begun to test a new treatment for patients with uncontrolled high blood pressure. The study, called Zenith Phase III, will involve around 11,000 participants across 35 countries. Its goal is to lower the risk of serious heart and blood vessel problems in those struggling to manage their condition.

The trial marks a key step for Roche, which will receive a $300 million payment after the first patient received treatment under a licensing deal.

The Zenith Phase III study focuses on a drug given by injection just under the skin. Patients will receive the treatment twice a year, a schedule designed for convenience and long-term management.

Unlike other recent trials, such as the METAHEART study (which included 450 clinics in 18 countries) or a separate kidney-focused trial, Zenith is dedicated solely to cardiovascular risks. No prior details about this specific study have been released, making its launch a notable development in hypertension research. With 11,000 participants, the trial will gather data from a wide range of patients. The large sample size aims to provide stronger evidence on whether the drug can effectively reduce major cardiovascular events in those with hard-to-control blood pressure.

The start of the Zenith Phase III trial triggers a $300 million milestone payment to Roche. If successful, the twice-yearly injection could offer a new option for patients who struggle with current treatments. The results will determine whether the drug moves closer to regulatory approval and wider use.